Theratechnologies (TSX: TH) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides.
Portfolio of Products
Our lead product, EGRIFTA® (tesamorelin for injection), is the first and only treatment approved by the U.S. Food and Drug Administration indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA® is exclusively commercialized in the United States by EMD Serono, Inc. pursuant to a collaboration and licensing agreement. EGRIFTA® is our trademark and is the proposed brand name to be used globally in connection with the commercialization of tesamorelin for injection for this treatment, if approved.*
Our strategy is now focused on the regulatory approval and commercialization of tesamorelin in additional HIV-associated lipodystrophy markets (including Europe, Canada and Latin America).
Theratechnologies has adopted a sound financial strategy governing cash position and cash flow management. Maintaining a solid balance sheet is a corporate priority that underpins Theratechnologies’ strategy.
*Please note that EGRIFTA® has not received approval for use from Health Canada and other regulatory agencies around the world, except in the United States. U.S. patients and/or U.S. healthcare professionals seeking information on EGRIFTA® should refer to EMD Serono, Inc. for more information.